Pfizer supports deployment of 400 oxygen beds in Delhi, 30-bed ICU facility in Mumbai

With a grant of Rs 4.5 crore from Pfizer, Doctors For You has procured and deployed 400 high-quality beds with oxygen support and other medically necessary equipment and services of medical and paramedical staff services.
1 CLAP
0

Global pharma major Pfizer on Monday said it has partnered with the non-governmental organisation, Doctors For You, to help create 400 oxygen bed capacity at Delhi's Yamuna COVID care centre.

With a grant of Rs 4.5 crore from Pfizer, Doctors For You has procured and deployed about 400 high-quality beds with oxygen support and other medically necessary equipment and services of medical and paramedical staff services to maintain the operations at the facility, the company said in a statement.

10 per cent of these beds have been set up to specifically meet the requirements of COVID-19 paediatric patients, it added.

In addition to the aid provided by Pfizer India, the US-based Pfizer Foundation, donated $ 500,000 (Rs 4 crore) grant to AmeriCares to support a 30-bed ICU facility at the Bandra Kurla Complex Jumbo COVID Centre in Mumbai, the statement said.

The foundation also provided a $ 500,000 grant to direct relief to fund the support, acquisition, and distribution of critical medicines, medical supplies including oxygen and PPE, it added.

"Pfizer is firmly committed to supporting India in its fight against the pandemic. We stand in solidarity with all those currently affected by COVID-19 in India and around the world and will continue to do everything possible to provide assistance in India''s fight against COVID-19," Pfizer Ltd MD S Sridhar said.

Earlier in May, Pfizer had indicated the availability of 5 crore vaccines - 1 crore in July, 1 crore in August, 2 crores in September and 1 crore in October - for supply to India in 2021 and that it will deal only with Government of India and payment for vaccines will have to be made by GOI to Pfizer India.

The central government will make its own arrangement for further channelisation of procured vaccines in the domestic market.

(Disclaimer: Additional background information has been added to this PTI copy for context)

Edited by Anju Narayanan